About University of California - Davis Medical Center
UC Davis Medical Center is part of UC Davis Health and a major academic health center located in Sacramento, California. It is owned and operated by the University of California as part of its University of California, Davis campus.
There are 625 beds in University of California - Davis Medical Center.
Clinical Trials at University of California - Davis Medical Center
During the past decade, University of California - Davis Medical Center conducted 362 clinical trials. In the 10-year time frame, 362 clinical trials started and 213 clinical trials were completed, i.e. on
average, 58.8% percent of trials that started reached the finish line to date. In the past 5 years, 158 clinical trials started and 138 clinical trials were completed. i.e. 87.3%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "University of California - Davis Medical Center" #1 sponsor was "University of California, Davis" with 148 trials, followed by "SWOG Cancer Research Network" with 39 trials
sponsored, "Pfizer" with 24 trials sponsored, "Gilead Sciences" with 21 trials sponsored and "Children's Oncology Group"
with 21 trials sponsored. Other sponsors include 461 different institutions and
companies that sponsored additional 255 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "University of California - Davis Medical Center"
#1 collaborator was "National Cancer Institute (NCI)" with 71 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 18 trials as a collaborator, "University of California, Davis" with 11 trials as a collaborator, "SWOG Cancer Research Network" with 10 trials as a collaborator and "Medical University of South Carolina" with 9 trials as a collaborator. Other collaborators include 349 different institutions and companies that were
collaborators in the rest 248 trials.
Clinical Trials Conditions at University of California - Davis Medical Center
According to Clinical.Site data, the most researched conditions in "University of California - Davis Medical Center" are
"HIV Infections" (29 trials), "Duchenne Muscular Dystrophy" (17 trials), "Pulmonary Arterial Hypertension" (17 trials), "Pulmonary Hypertension" (15 trials) and "Lymphoma" (14 trials). Many other conditions were trialed in "University of California - Davis Medical Center" in a lesser frequency.
Clinical Trials Intervention Types at University of California - Davis Medical Center
Most popular intervention types in "University of California - Davis Medical Center" are "Drug" (427 trials), "Device" (107 trials), "Biological" (79 trials), "Other" (69 trials) and "Procedure" (51 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (118 trials), "etoposide" (17 trials), "filgrastim" (17 trials), "cyclophosphamide" (16 trials) and "radiation therapy" (15 trials). Other intervention names were less common.
Clinical Trials Genders at University of California - Davis Medical Center
The vast majority of trials in "University of California - Davis Medical Center" are
637 trials for "All" genders, 40 trials for "Male" genders and 39 trials for "Female" genders.
Clinical Trials Status at University of California - Davis Medical Center
Currently, there are 164 active trials in "University of California - Davis Medical Center".
3 are not yet recruiting,
103 are recruiting,
53 are Active, not recruiting,
and 5 are Enrolling by invitation.
In total, there were 422 completed trials in University of California - Davis Medical Center,
undefined suspended trials,
and 98 terminated clinical trials to date.
Out of the total trials that were conducted in University of California - Davis Medical Center, 60 "Phase 1"
clinical trials were conducted, 207 "Phase 2" clinical
trials and 223 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 32 trials, and there were
also 138 trials that are defined as “Not Applicable".